Skip to main content

NU SKIN ENTERPRISES INC

For the period ended Dec 31, 2023. Filed Feb 15, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 15, 2024

NUS$4.28+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

GEOGRAPHIC REGIONS

We currently sell and distribute our Nu Skin business’s products in nearly 50 markets. We have divided our markets into seven segments: Mainland China; South Korea; Southeast Asia/Pacific, which includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Australia, New Zealand and other markets; Americas, which includes Canada, Latin America and the United States; Japan; Hong Kong/Taiwan, which also includes Macau; and Europe & Africa, which includes markets in Europe as well as South Africa. Our Rhyz business arm also includes two additional segments: Manufacturing and Rhyz other. The following table sets forth the revenue for each of the segments and the Other category for the last three years.

Year Ended December 31,
(U.S. dollars in millions) · 2023 · 2022 · 2021
Nu Skin
Americas$398.220%$508.523%$547.820%
Mainland China298.115360.416568.821
Southeast Asia/Pacific267.214344.416336.713
South Korea236.112268.712354.313
Japan207.810224.910266.210
Europe & Africa192.410204.39283.211
Hong Kong/Taiwan153.68157.27162.66
Other(0.9)—4.0—3.5—
Total Nu Skin1,752.5892,072.4932,523.194
Rhyz
Manufacturing181.49149.57172.16
Rhyz other35.22%3.8—0.5—
Total Rhyz216.611153.37172.66
Total$1,969.1100%$2,225.7100%$2,695.7100%

Additional comparative revenue and related financial information is presented in Note 15 to the consolidated financial statements contained in this report.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.